POSB63 Analysis of Cost per PASI75 and per Dlqi 0/1 Responder over 52 WEEKS in Patients with Moderate Plaque Psoriasis Initiated on Apremilast, Remaining on Apremilast or Switching to Biologics, and Patients Hypothetically Treated with Biologics AB Initio, Based on the Results of the Apraisal Multicenter Observational Study in Greece

• DOI: 10.1016/j.jval.2021.11.336
• Publication Date: 2022-01-19T19:14:45Z
• Authors: E Sotiriou; V Chasapi; E Gialeli; J Katsantonis; E Lazaridou; N Rompoti; O Neofotistou; A Drosos; KD Tomai; E Rovithi; C Kalinou; E Papadavid; P Aronis; M Papageorgiou; A Protopapa; K Mavridou; I Lefaki; E Zafiriou; K Krasagakis; E Pokas; A Kekki; Z Anagnostopoulos; N Antonakopoulos; M Papakonstantis
• Keywords: 03 medical and health sciences; 0302 clinical medicine